MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584510 | Name: Dilazep

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dilazep is a coronary vasodilator with some antiarrhythmic activity.

Chemical Structure

Dilazep
CAS#35898-87-4 (free base)

Theoretical Analysis

MedKoo Cat#: 584510

Name: Dilazep

CAS#: 35898-87-4 (free base)

Chemical Formula: C31H44N2O10

Exact Mass: 604.2996

Molecular Weight: 604.70

Elemental Analysis: C, 61.57; H, 7.33; N, 4.63; O, 26.46

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
35898-87-4 (free base) 20153-98-4 (HCl)
Synonym
Dilazep; Dilazepam; Dilazepum; AS 05; AS05; AS-05;
IUPAC/Chemical Name
3-[4-[3-(3,4,5-trimethoxybenzoyl)oxypropyl]-1,4-diazepan-1-yl]propyl 3,4,5-trimethoxybenzoate
InChi Key
QVZCXCJXTMIDME-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H44N2O10/c1-36-24-18-22(19-25(37-2)28(24)40-5)30(34)42-16-8-12-32-10-7-11-33(15-14-32)13-9-17-43-31(35)23-20-26(38-3)29(41-6)27(21-23)39-4/h18-21H,7-17H2,1-6H3
SMILES Code
O=C(OCCCN1CCN(CCCOC(C2=CC(OC)=C(OC)C(OC)=C2)=O)CCC1)C3=CC(OC)=C(OC)C(OC)=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 604.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Playa H, Lewis TA, Ting A, Suh BC, Muñoz B, Matuza R, Passer BJ, Schreiber SL, Buolamwini JK. Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2). Bioorg Med Chem Lett. 2014 Dec 15;24(24):5801-5804. doi: 10.1016/j.bmcl.2014.10.026. Epub 2014 Oct 28. PubMed PMID: 25454272; PubMed Central PMCID: PMC5695681. 2: Zeng H, Liu S, Wang P, Qu X, Ji H, Wang X, Zhu X, Song Z, Yang X, Ma Z, Zhu H. Dilazep synergistically reactivates latent HIV-1 in latently infected cells. Mol Biol Rep. 2014 Nov;41(11):7697-704. doi: 10.1007/s11033-014-3662-z. Epub 2014 Aug 5. PubMed PMID: 25091947. 3: Hoque AN, Hoque N, Hara A, Hashizume H, Ichihara K, Abiko Y. Cardioprotective effect of K-7259, a novel dilazep derivative, against ischemia-reperfusion damage in isolated, working rat hearts. Jpn J Pharmacol. 1997 Apr;73(4):365-9. PubMed PMID: 9165376. 4: Sambhi MP, Kannan R, Thananopavarn C, Ookhtens M, Gudenzi M. Therapeutic tolerance, hemodynamic effects, and oral dose kinetics of dilazep dihydrochloride in hypertensive patients. J Pharm Sci. 1989 Apr;78(4):281-4. PubMed PMID: 2724090. 5: Hayashi T, Kaneko S, Thang NT, Shou I, Shirato I, Tomino Y. Effect of dilazep hydrochlorideon the Im munohistopathology of IgA nephropathy in ddY mice. Nephron. 2000 Nov;86(3):327-32. PubMed PMID: 11096290. 6: Nakatsuka R, Nozaki T, Shinohara M, Ohura K. Dilazep decreases lipopolysaccharide-induced nitric oxide and TNF-alpha synthesis in RAW 264 cells. J Pharmacol Sci. 2010;113(3):271-5. PubMed PMID: 20647687. 7: Ho HT, Xia L, Wang J. Residue Ile89 in human plasma membrane monoamine transporter influences its organic cation transport activity and sensitivity to inhibition by dilazep. Biochem Pharmacol. 2012 Aug 1;84(3):383-90. doi: 10.1016/j.bcp.2012.04.018. Epub 2012 May 4. PubMed PMID: 22562044; PubMed Central PMCID: PMC3372611. 8: Grasso S, Cefis M, Fonte S, Ugolini C, Cerri B. Efficacy of Dilazep in patients with previous myocardial infarction participating in a cardiac rehabilitation programme. Int J Clin Pharmacol Res. 1983;3(4):271-4. PubMed PMID: 6678824. 9: Numabe A, Ara N, Hakamada-Taguchi R, Suzuki N, Hirawa N, Kawabata Y, Negoro T, Nagata T, Goto A, Toyo-Oka T, Fujita T, Uehara Y. Effects of the anti-platelet aggregation drug dilazep on cognitive function in Dahl salt-sensitive rats. Hypertens Res. 2003 Feb;26(2):185-91. PubMed PMID: 12627880. 10: Opartkiattikul N, Sukpanichnant S, Wanachiwanawin W, Fucharoen S, Funahara Y, Sumiyoshi A, Imai K, Sangtawesin W, Thientadakul P. A double-blind placebo control trial of dilazep in beta-thalassemia/hemoglobin E patients. Southeast Asian J Trop Med Public Health. 1997;28 Suppl 3:167-71. PubMed PMID: 9640622. 11: Tonini M, Perucca E, Manzo L, Marcoli M, D'Angelo L, Saltarelli P, Onori L. Dilazep: an inhibitor of adenosine uptake with intrinsic calcium antagonistic properties. J Pharm Pharmacol. 1983 Jul;35(7):434-9. PubMed PMID: 6136584. 12: Pandhi P, Biswas NR, Wahi PL, Sharma PL. Controlled clinical trial of nifedipine alone and in combination with dilazep in patients with angina pectoris. Int J Clin Pharmacol Ther Toxicol. 1991 Nov;29(11):454-6. PubMed PMID: 1800394. 13: Kawabata M, Haneda M, Wang T, Imai M, Takabatake T. Effects of a nucleoside transporter inhibitor, dilazep, on renal microcirculation in rats. Hypertens Res. 2002 Jul;25(4):615-21. PubMed PMID: 12358150. 14: Zhou H. Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome. Acta Pharmacol Sin. 2004 Oct;25(10):1366-71. PubMed PMID: 15456541. 15: Tanabe S, Tamaki T, Wada Y, Sumiyoshi A, Funahara Y. Cytoprotective effect of dilazep on hydrogen peroxide-perturbed vascular endothelial cells. Southeast Asian J Trop Med Public Health. 1992;23 Suppl 2:120-6. PubMed PMID: 1298985. 16: Carleo R, Buda GR, Cerciello A, Dell'Aversano R, Monaco GP, Trovato C, Vigilante M. [The effect of dilazep on circulating platelet aggregation in diabetics]. Boll Soc Ital Biol Sper. 1983 Dec 30;59(12):1832-7. Italian. PubMed PMID: 6671042. 17: Nakamura T, Ushiyama C, Takahashi Y, Tanaka A, Shimada N, Ebihara I, Koide H. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron. 2001 May;88(1):80-2. PubMed PMID: 11340355. 18: Nakamoto H, Ogasawara Y, Kajiya F. Visualisation of the effects of dilazep on rat afferent and efferent arterioles in vivo. Hypertens Res. 2008 Feb;31(2):315-24. doi: 10.1291/hypres.31.315. PubMed PMID: 18360052. 19: Yoshida H, Kanatsu K, Muso E, Kuwahara T, Sekita K, Ono T, Konishi N, Kanda C, Minakata T, Morimoto K, et al. Effects of an anti-platelet drug (dilazep) in IgA nephropathy: comparison of clinical effects with renal biopsy findings. Nihon Jinzo Gakkai Shi. 1994 Apr;36(4):339-44. PubMed PMID: 8022106. 20: Shuralyova I, Tajmir P, Bilan PJ, Sweeney G, Coe IR. Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole. Am J Physiol Heart Circ Physiol. 2004 Feb;286(2):H627-32. Epub 2003 Oct 9. PubMed PMID: 14551048.

View History

Diallylcyanamide

Diallylcyanamide

Featured